| Document |
Document Title |
|
WO/2010/113834A1 |
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...
|
|
WO/2010/111845A1 |
Provided are a high specific activity human menopausal gonadotropin, as well as preparation method and use thereof. The specific activity of said high specific activity menopausal gonadotropin is no less than 5000 FSH UI/mg protein. Also...
|
|
WO2010110440A1 |
Disclosed is a prophylactic and/or therapeutic agent for cognitive impairment including dementia of the Alzheimer type, which comprises 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)- 1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid ...
|
|
WO/2010/110689A1 |
The invention relates to the use of kynurenic acid derivatives of general formula (I), wherein R1 is hydroxy, NHR2, NR2R2 or C1-10 straight or branched alkoxy or glyceryl group; R2 is hydrogen atom or C1-10 straight or branched alkyl gro...
|
|
WO/2010/110639A1 |
A comestible composition with phytoestrogenic property against oxidative stress, retarding hormone related cancer, affecting fertility and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a decreas...
|
|
WO2010110479A1 |
A compound represented by general formula (A) or a pharmacologically acceptable salt thereof which is to be used as an activator for PPAR. In general formula (A), W represents O or S; X represents CH or N; R8 represents an alkyl group ha...
|
|
WO/2010/108107A1 |
The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furo...
|
|
WO/2010/106383A1 |
The present invention relates to novel crystalline Form A of 17α-acetoxy-21-methoxy- l lβ-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-
dione, (also known as CDB-4124) and methods for the preparation of it in excellent purity.
|
|
WO/2010/102554A1 |
A new crystalline form of Agomelatine, its preparation method and application are provided. There are main peaks where diffraction angles 2θ are 11.13, 11.82, 17.49, 18.29, 19.48, 19.72, 20.50, 21.76, 22.54, 22.97, 24.56, 25.36, 27.16 a...
|
|
WO/2010/103045A1 |
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum...
|
|
WO/2010/104721A1 |
The present invention provides a compound of the formula: Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and ...
|
|
WO/2010/101949A1 |
Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, ...
|
|
WO/2010/101127A1 |
Provided is a compound useful in medicinal compositions, for example, remedies for diseases in which 17βHSD type 5 participates. As the results of intensive studies on compounds possibly useful as remedies for diseases in which 17βHSD ...
|
|
WO/2010/094821A1 |
The invention relates to the use of vaginally-administered insulin-sensitizing agents for preventing and/or treating hyperandrogenism and/or polycystic ovarian syndrome and/or related disorders.
|
|
WO/2010/095425A1 |
Provided is a method for producing crystals of a vitamin D derivative represented by formula (I), with which the production can be performed economically in a shorter time than the conventional methods. A crude material of the vitamin D ...
|
|
WO/2010/092440A1 |
The present invention relates to CXCR2 receptor antagonists or inhibitors of CXCR2 receptor gene expression for the treatment or the prevention of insulin resistance. The present invention also relates to a method for diagnosing and/or p...
|
|
WO/2010/091637A1 |
Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by e...
|
|
WO/2009/082437A9 |
Provided herein are compounds of formulae I to II that bind to androgen receptors and/or modulate activity of androgen receptors; and to methods for making and using such compounds. Also provided are compositions including such compounds...
|
|
WO/2010/088574A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2010/088450A2 |
Provided herein are compounds, compositions, and methods for treating or ameliorating diseases associated with the modulation of SERCA.
|
|
WO/2010/086972A1 |
Provided is a safe and effective antistress agent which relieves responses in vivo caused by stress loading. An antistress agent or an antagonist or reliever against physical and mental disorders caused by loads in vivo, characterized by...
|
|
WO/2010/086129A1 |
The present invention relates to Inclusion complexes comprising cyclodextrin, preferably gamma-cyclodextrin and cinacalcet, wherein the molar ratio of cyclodextrin to cinacalcet is 1 : 1 to 5 : 1, preferably about 1 : 2. The invention fu...
|
|
WO/2010/084999A1 |
Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases, which contain the substances (for example, anti-galectin-9 antibody, anti-Tim-3 antibody, RNA and DNA aptamers and low molecular substances) blocki...
|
|
WO/2010/085145A1 |
The present invention relates to a method for the prophylaxis or treatment of a subject for flushing, wherein a pharmaceutical agent having LHRH antagonistic activity is administered to said subject at a dosage of less than 15 µg/kg/day...
|
|
WO/2010/084120A1 |
This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic ac...
|
|
WO/2010/080537A1 |
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
|
|
WO/2010/078833A1 |
Provided are a modified Na-montmorillonite and a preparation method thereof, wherein Na+ content is not less than 2.0% based on Na2O in the modified Na-montmorillonite. The modified Na-montmorillonite has a more reasonable microstructure...
|
|
WO/2010/077947A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2010/078285A2 |
A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain ...
|
|
WO/2010/077686A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2010/074284A1 |
By searching for a number of various compounds having an activity of inhibiting IL-12/IL-23 production, provided are a medicinal composition and a drug for treating or preventing a disease relating to the hyperproduction of IL-12/IL-23, ...
|
|
WO/2010/074361A1 |
The present invention relates to a pharmaceutical composition for preventing or treating a menopausal symptom, comprising cinnamic acid, shanzhiside methylester or a mixture thereof as an active ingredient. The composition of the present...
|
|
WO/2010/074089A1 |
Provided are novel low-molecular compounds which exhibit calcium receptor antagonist activity, and which are highly safe and orally administrable, namely, compounds having general formula (I) or pharmacologically acceptable salts thereof...
|
|
WO/2010/074088A1 |
Provided are novel low-molecular compounds which exhibit calcium receptor antagonist activity, and which are highly safe and orally administrable, namely, compounds having general formula (I) or pharmacologically acceptable salts thereof...
|
|
WO/2010/069139A1 |
The present invention discloses a pharmaceutical composition containing a complex of cycloartenyl ferulate and 24-methylene cycloartanyl ferulate, phospholipids, cholic acids and/or salts thereof. The water-solubility and the stability o...
|
|
WO/2010/070022A1 |
The present invention relates to novel compounds of general formula (I), in which A, U, V, X, Y, R1, R2, and R3 are defined as described below, and to tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, salts and hydrates...
|
|
WO/2010/069138A1 |
The present invention discloses a pharmaceutical composition containing oryzanol, phospholipids, cholic acids and/or salts thereof. The water-solubility and the stability of oryzanol have been effectively improved by being prepared into ...
|
|
WO/2010/071853A1 |
Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide varie...
|
|
WO/2010/068500A2 |
Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl
) propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and usi...
|
|
WO/2010/066852A1 |
A composition comprising at least one isoflavone, phloridzin and one or more probiotics. A composition as described herein is also provided for internal use as a natural alternative to hormone replacement therapy and for treating disorde...
|
|
WO/2010/065567A2 |
Described herein are the results of comprehensive genetic expression and other molecular analysis of the effect of antioxidants on biological systems, including specifically different human cells. Based on these analyses, methods and com...
|
|
WO/2010/061971A1 |
Provided is a novel JAK3 inhibitor useful as a preventive and/or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren’s synd...
|
|
WO/2010/061030A1 |
The invention relates to the isolation of multipotent hypophysary cells and to the in vitro differentiation thereof. The method is based on the presence in multipotent hypophysary cells of a receptor of the external face of the membrane,...
|
|
WO/2010/060836A1 |
The present invention is concerned with arylcyclohexylethers of dihydro-tetraazabenzoazulene derivatives, i.e. arylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives of formula (I) wherein R1, R2 and R3 are...
|
|
WO/2010/057260A1 |
The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and / or progeny cells thereof and / or soluble factors derived ther...
|
|
WO/2010/056549A1 |
The present invention provides novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases a...
|
|
WO/2010/054565A1 |
The present invention provides the water-soluble prodrug of (R)-(-)-bicalutamide as follows of formula (I), its pharmaceutically acceptable salts, its preparation method and uses thereof. The compound of formula (I) is useful for treatme...
|
|
WO/2010/054438A1 |
Compounds of formula (I): wherein R1 and R4 are OR7, R2 and R3 are H or OR7, with the proviso that when R2 is OR7 then R3 is H, and when R3 is OR7 then R2 is H; R5 and R6 are independently H, OH, or OR7 with the proviso that when R5 is O...
|
|
WO/2010/052563A2 |
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of incr...
|
|
WO/2010/054286A2 |
The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof. Formula (I).
|
